Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Eli Lilly has today forecast annual profit largely above Wall Street estimates, providing some relief to investors after ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

On the charts, today's pop has NVO on track to snap a three-day losing streak. The stock still hasn't recovered from its ...